Abstract
A series of 5-halogenomethylsulfonylbenzimidazole and benzotriazole derivatives was synthesized as potential antibacterial agents. A new method of synthesis of benzimidazoles was developed. The antimicrobial activities of these compounds were tested against a series of reference and clinical strains. The reference strains include Gram-positive bacteria (S. aureus, S. epidermidis, B. subtilis, B. cereus, E. hirae, M. luteus) and Gram-negative rods (E. coli, P. vulgaris, P. aeruginosa, B. bronchiseptica). The clinical strains include six methicillin-resistant (MRSA) and two methicillin-sensitive (MSSA) S. aureus strains, one methicillin-resistant S. epidermidis, three E. faecalis and two E. faecium strains. Compound with trifluoromethyl- substituent at C-2 position (4) displayed significant antibacterial activities comparable with nitrofurantoin against four strains, and higher against Micrococcus luteus. MIC values for clinical Staphylococci strains (MRSA) were 12.5-25 μg/mL; for Enterococcus strains these values were 50-100 μg/mL. MIC values for reference and clinical strains of Staphylococcus and Enterococcus group were similar, respectively.
Keywords: 5-Halogenomethylsulfonylbenzimidazole and benzotriazole derivatives, Amberlyst 15, Antibacterial activity, MRSA, MSSA, Nitrofurantoin.
Medicinal Chemistry
Title:Synthesis and in vitro Antibacterial Activity of 5-Halogenomethylsulfonyl- Benzimidazole and Benzotriazole Derivatives
Volume: 9 Issue: 8
Author(s): Zbigniew Ochal, Maria Bretner, Renata Wolinowska and Stefan Tyski
Affiliation:
Keywords: 5-Halogenomethylsulfonylbenzimidazole and benzotriazole derivatives, Amberlyst 15, Antibacterial activity, MRSA, MSSA, Nitrofurantoin.
Abstract: A series of 5-halogenomethylsulfonylbenzimidazole and benzotriazole derivatives was synthesized as potential antibacterial agents. A new method of synthesis of benzimidazoles was developed. The antimicrobial activities of these compounds were tested against a series of reference and clinical strains. The reference strains include Gram-positive bacteria (S. aureus, S. epidermidis, B. subtilis, B. cereus, E. hirae, M. luteus) and Gram-negative rods (E. coli, P. vulgaris, P. aeruginosa, B. bronchiseptica). The clinical strains include six methicillin-resistant (MRSA) and two methicillin-sensitive (MSSA) S. aureus strains, one methicillin-resistant S. epidermidis, three E. faecalis and two E. faecium strains. Compound with trifluoromethyl- substituent at C-2 position (4) displayed significant antibacterial activities comparable with nitrofurantoin against four strains, and higher against Micrococcus luteus. MIC values for clinical Staphylococci strains (MRSA) were 12.5-25 μg/mL; for Enterococcus strains these values were 50-100 μg/mL. MIC values for reference and clinical strains of Staphylococcus and Enterococcus group were similar, respectively.
Export Options
About this article
Cite this article as:
Ochal Zbigniew, Bretner Maria, Wolinowska Renata and Tyski Stefan, Synthesis and in vitro Antibacterial Activity of 5-Halogenomethylsulfonyl- Benzimidazole and Benzotriazole Derivatives, Medicinal Chemistry 2013; 9 (8) . https://dx.doi.org/10.2174/1573406411309080015
DOI https://dx.doi.org/10.2174/1573406411309080015 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulation of the TRPV1 Channel: Current Clinical Trials and Recent Patents with Focus on Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) Transdermal Drug Delivery: A Step towards Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery GSK-3 Inhibitors as New Leads to Treat Type-II Diabetes
Current Drug Targets Identification of Antifungal Agents Using Combinatorial Approach: An Overview$
Current Medicinal Chemistry - Anti-Infective Agents N-Hydroxyguanidines as Substrates of Nitric Oxide Synthases
Current Topics in Medicinal Chemistry The Endocannabinoid System in Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Macrocyclic Inhibitors of Hsp90
Current Topics in Medicinal Chemistry Targeting Virus-Induced Reprogrammed Cell Metabolism <i>via</i> Glycolytic Inhibitors: An Effective Therapeutic Approach Against SARS-CoV-2
Mini-Reviews in Medicinal Chemistry From Stem Cell Biology to The Treatment of Lung Diseases
Current Stem Cell Research & Therapy Withdrawal Notice: The Relationship between Opium Use and Coronavirus Infection: A Brief Research Report from Iran
Coronaviruses Revealing Insights into Natural Products Against mcr-1-Producing Bacteria
Current Drug Targets Antineoplastic Activity, Structural Modification, Synthesis and Structure-activity Relationship of Dammarane-type Ginsenosides: An Overview
Current Organic Chemistry New Perspectives on Biomedical Applications of Iron Oxide Nanoparticles
Current Medicinal Chemistry Mental Disorders and Poor COVID-19 Prognosis: Reevaluating the Relationship through Ca<sup>2+</sup>/cAMP Signalling
Current Topics in Medicinal Chemistry Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Coumarin-based Scaffold as α-glucosidase Inhibitory Activity: Implication for the Development of Potent Antidiabetic Agents
Mini-Reviews in Medicinal Chemistry Fluoroquinolones as Chemotherapeutics Against Mycobacterial Infections
Current Pharmaceutical Design Ivabradine in the Management of COVID-19-related Cardiovascular Complications: A Perspective
Current Pharmaceutical Design Recent Developments of Quinoline Derivatives and their Potential Biological Activities
Current Organic Synthesis Human Cancer Cell Line Based Approach of 1,3,4-thiadiazole and its Fused Ring: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry